dupilumab
Selected indexed studies
- Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. (Expert Rev Respir Med, 2022) [PMID:35703018]
- Dupilumab for treatment of atopic dermatitis. (Expert Rev Clin Pharmacol, 2018) [PMID:29557246]
- Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. (Dermatology, 2023) [PMID:37100035]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. (2022) pubmed
- Dupilumab for treatment of atopic dermatitis. (2018) pubmed
- Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review. (2023) pubmed
- Dupilumab-associated inflammatory arthritis: a literature review. (2024) pubmed
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. (2022) pubmed
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. (2017) pubmed
- Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. (2022) pubmed
- Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. (2024) pubmed
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. (2019) pubmed
- Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. (2022) pubmed